Hedgehog Signaling Pathway Research Reagents

SHH (Sonic Hedgehog) — The most extensively studied and broadly expressed Hh ligand. SHH acts as a morphogen during neural tube ventralization, limb digit patterning, and craniofacial development, where it forms a concentration gradient that specifies distinct cell fates in a dose-dependent manner. SHH undergoes dual lipid modification — cholesterol at the C-terminus and palmitate at the N-terminus — which are required for proper gradient formation and signaling potency. Recombinant SHH (typically the N-terminal signaling domain, SHH-N) is used in neural progenitor differentiation, organoid patterning, and pathway activation assays.
→ Browse SHH antibodies & proteins

IHH (Indian Hedgehog) — A critical regulator of endochondral ossification that coordinates chondrocyte proliferation and hypertrophic differentiation in the growth plate through a feedback loop with parathyroid hormone-related protein (PTHrP). IHH mutations cause brachydactyly type A1 and acrocapitofemoral dysplasia.
→ Browse IHH antibodies & proteins

DHH (Desert Hedgehog) — The most tissue-restricted Hh ligand, primarily expressed in Sertoli cells and Schwann cells. DHH is essential for male gonadal differentiation and peripheral nerve sheath formation. DHH mutations cause 46,XY gonadal dysgenesis with or without polyneuropathy.
→ Browse DHH antibodies & proteins

PTCH1 (Patched 1) — A twelve-pass transmembrane receptor that functions as the primary Hh ligand-binding receptor and a constitutive repressor of SMO. In the absence of ligand, PTCH1 inhibits SMO through a mechanism involving cholesterol transport regulation at the primary cilium. Hh ligand binding to PTCH1 relieves this repression, allowing SMO activation. PTCH1 is also a direct transcriptional target of GLI, forming a negative feedback loop. Loss-of-function mutations in PTCH1 cause Gorlin syndrome (nevoid basal cell carcinoma syndrome) and are found in the majority of sporadic BCCs.
→ Browse PTCH1 antibodies & proteins

SMO (Smoothened) — A class F G protein-coupled receptor (GPCR) family member that is the essential positive transducer of Hedgehog signaling. Upon release from PTCH1 inhibition, SMO undergoes conformational activation, ciliary accumulation, and phosphorylation, initiating downstream GLI activation. SMO is the target of FDA-approved small-molecule inhibitors vismodegib and sonidegib for advanced BCC. SMO gain-of-function mutations (e.g., D473H, W535L) can confer resistance to these inhibitors.
→ Browse SMO antibodies & proteins

BOC / CDO (CDON) — Immunoglobulin/fibronectin superfamily co-receptors that bind SHH and promote pathway activation by facilitating ligand–PTCH1 interaction. BOC and CDO are particularly important for SHH-dependent neural tube patterning and myogenic differentiation. CDO mutations have been identified in holoprosencephaly patients, underscoring their role in midline development.
→ Browse BOC / CDO antibodies & proteins

GLI1 — A zinc-finger transcription factor that functions exclusively as a transcriptional activator and is itself a direct Hh target gene. GLI1 expression level is therefore a reliable and widely used readout for pathway activity by qPCR and IHC. GLI1 amplification was originally identified in glioblastoma, and GLI1 overexpression is observed across multiple Hh-driven tumors. Unlike GLI2 and GLI3, GLI1 is not proteolytically processed into a repressor form.
→ Browse GLI1 antibodies & proteins

GLI2 / GLI3 — Bifunctional transcription factors that can act as either activators (GLI-A) or repressors (GLI-R) depending on Hh pathway status. In the absence of Hh signaling, GLI2 and GLI3 are phosphorylated by PKA, CK1, and GSK-3β, promoting their proteolytic processing to C-terminally truncated repressor forms. GLI2 is the primary activator of initial Hh target gene transcription, while GLI3 repressor (GLI3-R) is the principal repressor in the pathway-off state. The GLI3-A/GLI3-R ratio is a key determinant of digit patterning, and GLI3 mutations cause Pallister-Hall syndrome and Greig cephalopolysyndactyly.
→ Browse GLI2 / GLI3 antibodies & proteins

SUFU (Suppressor of Fused) — The major cytoplasmic negative regulator of mammalian Hedgehog signaling. SUFU directly binds GLI proteins, sequestering them in the cytoplasm and promoting GLI3 processing to its repressor form. SUFU acts downstream of SMO, meaning that SUFU loss-of-function renders pathway activation independent of both PTCH1 and SMO. Germline SUFU mutations predispose to medulloblastoma (desmoplastic/nodular subtype) and are found in a subset of Gorlin syndrome families without PTCH1 mutations. Because SUFU acts downstream of SMO, SUFU-mutant tumors are intrinsically resistant to SMO inhibitors.
→ Browse SUFU antibodies & proteins

HHIP (Hedgehog-Interacting Protein) — A membrane-bound glycoprotein that binds all three Hh ligands and attenuates pathway signaling. HHIP is a direct GLI target gene that forms a negative feedback loop, similar to PTCH1. HHIP is frequently silenced by promoter methylation in gastrointestinal and hepatocellular cancers, removing a brake on paracrine Hh signaling in the tumor microenvironment.
→ Browse HHIP antibodies & proteins

1. Briscoe J, Thérond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 2013;14(7):416-429. DOI

2. Hahn H, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841-851. DOI

3. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov. 2006;5(12):1026-1033. DOI

4. Pak E, Bhatt DK, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev Cell. 2019;8(3):352-372. DOI